NTEC has been the topic of several other research reports. Maxim Group set a $8.00 price target on shares of Intec Pharma and gave the stock a buy rating in a research note on Friday, November 17th. Zacks Investment Research upgraded shares of Intec Pharma from a sell rating to a hold rating in a research note on Friday, September 22nd. CIBC reiterated an outperform rating and set a $15.00 price target (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Finally, ValuEngine cut shares of Intec Pharma from a hold rating to a sell rating in a research note on Thursday, November 16th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $10.70.
Shares of Intec Pharma (NASDAQ:NTEC) traded up $0.10 during trading on Monday, hitting $5.10. 62,900 shares of the stock traded hands, compared to its average volume of 49,593. Intec Pharma has a 1-year low of $4.20 and a 1-year high of $9.80.
ILLEGAL ACTIVITY WARNING: “Intec Pharma (NTEC) Given a $15.00 Price Target at Oppenheimer” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/22/intec-pharma-ntec-given-a-15-00-price-target-at-oppenheimer.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.